Carrols Restaurant Group Inc
Change company Symbol lookup
Select an option...
TAST Carrols Restaurant Group Inc
CERN Cerner Corp
SOR Source Capital Inc
ADVM Adverum Biotechnologies Inc
JRO Nuveen Floating Rate Income Opportunity Fund
SND Smart Sand Inc
EMR Emerson Electric Co
ZM Zoom Video Communications Inc
CYCN Cyclerion Therapeutics Inc
FRCGF Faircourt Gold Income Corp
Go

Consumer Discretionary : Hotels, Restaurants & Leisure | Small Cap Value
Company profile

Carrols Restaurant Group, Inc. is a restaurant company. The Company is engaged in operating Burger King restaurants. The Company operates approximately 1,029 Burger King restaurants in 23 Northeastern, Midwestern, Southcentral and Southeastern states and 65 Popeyes restaurants in seven Southeastern states. Burger King restaurants features Whopper sandwich, as well as a variety of hamburgers, chicken and other specialty sandwiches, french fries, salads, breakfast items, snacks, soft drinks and other offerings. Popeyes Restaurants are quick-service restaurants offering a limited menu of lunch and dinner products, and in certain restaurants breakfast products. Its menu features a fried chicken sandwich, spicy chicken, chicken tenders, biscuits, fried shrimp and other seafood, red beans and rice and other quick-service menu items.

Price
Delayed
$2.47
Day's Change
-0.135 (-5.19%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.64
Day's Low
2.43
Volume
(Average)

Today's volume of 220,412 shares is on pace to be in-line with TAST's 10-day average volume of 247,846 shares.

220,412

SPPI FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Monday Deadline in Securities Class Action - SPPI

1:18 pm ET October 30, 2021 (Globe Newswire) Print

EQNX::TICKER_START EQNX::TICKER_END

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the "Class Period"), of the important November 1, 2021 lead plaintiff deadline.

SO WHAT: If you purchased Spectrum Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Spectrum Pharmaceuticals class action, go to http://www.rosenlegal.com/cases-register-2153.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 1, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facility of ROLONTIS (eflapegrastim), a long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia, maintained deficient controls and/or procedures; (2) the foregoing deficiencies decreased the likelihood that the U.S. Food and Drug Administration ("FDA") would approve the ROLONTIS Biologics License Application (the "ROLONTIS BLA") in its current form; (3) Spectrum Pharmaceuticals had therefore materially overstated the ROLONTIS BLA's approval prospects; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Spectrum Pharmaceuticals class action, go to http://www.rosenlegal.com/cases-register-2153.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

lrosen@rosenlegal.com

pkim@rosenlegal.com

cases@rosenlegal.com

www.rosenlegal.com

https://ml.globenewswire.com/media/745335af-3a3a-4fb5-84c0-fdedc9adf092/small/july-30-2021-rosen-logo-jpg.jpg

https://ml.globenewswire.com/media/745335af-3a3a-4fb5-84c0-fdedc9adf092/small/july-30-2021-rosen-logo-jpg.jpg

comtex tracking

COMTEX_396103305/2010/2021-10-30T13:18:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.